Spots Global Cancer Trial Database for PH 2 ADI-PEG 20 Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Official Title: Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Study ID: NCT01910012
Conditions
Interventions
Study Description
Brief Summary: Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers that require arginine. In this study, the investigators will evaluate the response rate, as determined by the revised International Working Group recommendations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
MD Anderson, Houston, Texas, United States
Chang Gung Medical Foundation-Kaohsiung, Kaohsiung City, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, , Taiwan
CMUH, Taichung, , Taiwan
NCKUH, Tainan City, , Taiwan
CGMH-LK, Taoyuan, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
